The drug, which prevents the virus from replicating, generated nearly $5 billion in sales for the US drug-maker in the first three quarters of 2022.The drug, which prevents the virus from replicating, generated nearly $5 billion in sales for the US drug-maker in the first three quarters of 2022.
Preliminary data from the study, carried out in the winter of 2021-2022 when the Omicron variant was dominant, was unveiled in October. In the latest study, led by University of Oxford researchers, nearly all of the more than 25 000 patients in the study had received at least three vaccine doses. There might be circumstances in which molnupiravir could be useful, for instance, in under-pressure health systems where it could be used to help key workers back to work quicker, said co-chief study investigator Chris Butler from the University of Oxford.